Related Experiment Videos

[Nephrotoxicity of anti-CD3 monoclonal antibodies]

M L Alegre1, M Depierreux, S Florquin

  • 1Département médico-chirurgical de Néphrologie, Hôpital Erasme.

Nephrologie
|January 1, 1991
PubMed

Insights

Monoclonal antibody OKT3 causes acute kidney injury during renal transplant rejection treatment. Pre-treating with corticosteroids, especially methylprednisolone, significantly reduces this nephrotoxicity by mitigating cytokine release.

Area of Science:

  • Nephrology
  • Immunology
  • Transplantation

Background:

  • The monoclonal antibody OKT3 is used to prevent or treat renal allograft rejection.
  • OKT3 administration can cause transient acute nephrotoxicity.
  • This nephrotoxicity is linked to cytokine release preceding immunosuppression.

Purpose of the Study:

  • To investigate the mechanism of OKT3-induced nephrotoxicity.
  • To evaluate the efficacy of corticosteroid pre-treatment in mitigating anti-CD3 antibody-related nephrotoxicity.

Main Methods:

  • Reproduced OKT3-like nephrotoxicity in mice using the 145-2C11 anti-CD3 antibody.
  • Administered varying doses of methylprednisolone prior to anti-CD3 antibody injection.
  • Monitored cytokine release and renal lesions.

Main Results:

  • Anti-CD3 antibody administration induced nephrotoxicity and systemic cytokine release in mice.
  • Corticosteroid pre-treatment dose-dependently reduced both cytokine release and nephrotoxicity.
  • Optimal protection was achieved with high-dose methylprednisolone (50 mg/kg) given 2-3 hours before the antibody.

Conclusions:

  • The nephrotoxicity associated with anti-CD3 monoclonal antibodies is mediated by cytokine release.
  • Corticosteroid pre-treatment is an effective strategy to prevent this adverse effect.
  • Specific dosing and timing of methylprednisolone are crucial for optimal nephroprotection.

Related Concept Videos